Apollon Wealth Management LLC bought a new stake in shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 61,772 shares of the company's stock, valued at approximately $253,000. Apollon Wealth Management LLC owned 0.15% of TuHURA Biosciences at the end of the most recent quarter.
Analyst Ratings Changes
HURA has been the topic of several research analyst reports. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a "strong-buy" rating in a research note on Thursday, December 19th. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They set a "buy" rating and a $11.00 target price on the stock. Finally, Maxim Group initiated coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They set a "buy" rating and a $15.00 target price on the stock.
Check Out Our Latest Stock Analysis on HURA
TuHURA Biosciences Price Performance
Shares of HURA traded down $0.49 during mid-day trading on Tuesday, hitting $3.70. The company's stock had a trading volume of 237,172 shares, compared to its average volume of 208,877. The company has a 50-day moving average of $4.55. TuHURA Biosciences has a fifty-two week low of $2.84 and a fifty-two week high of $14.60.
About TuHURA Biosciences
(
Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
